Trials / Unknown
UnknownNCT03967457
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Comprehensive Study on the Quality of Life in Cervical Cancer Patients: A Prospective Cohort Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,000 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is prospective cohort study. All the patients with primary cervical cancer in the future three years in Peking Union Medical College Hospital will be included in this study. Before and after the major therapy (including at least radical hysterectomy and/or radiotherapy), the patients accept (1) the questionnaires survey about quality of life; (2) urodynamic testing; (3) rectum dynamics testing and (4) ovarian reserve function. The survival outcomes (disease-free survival and overall survival) will be supplemented as secondary objectives.
Conditions
- Quality of Life
- Cervical Cancer
- Urodynamics
- Rectum Dynamics
- Sex Dysfunction
- Pelvic Floor Disorders
- Ovarian Reserve Function
- Survivorship
- Disease-free Survival
- Overall Survival
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | questionnaires survey | Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7) |
| DIAGNOSTIC_TEST | Urodynamic testing | Urodynamic testing consists of important urodynamic parameters including: Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume |
| DIAGNOSTIC_TEST | Rectum dynamics testing | Rectum dynamics testing consists of important parameters of rectum activities |
| DIAGNOSTIC_TEST | ovarian reserve function | Testing for ovarian reserve function consists of: Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B |
Timeline
- Start date
- 2019-06-19
- Primary completion
- 2022-06-01
- Completion
- 2023-06-01
- First posted
- 2019-05-30
- Last updated
- 2019-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03967457. Inclusion in this directory is not an endorsement.